Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEX-I plus aflibercept vs aflibercept for diabetic macular edema
ChiCTR2600123418Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in diabetic macular edema (DME) comparing Control: aflibercept monotherapy with aflibercept + dexamethasone intravitreal implant (2 arms). Primary endpoint: Change from baseline in central macular thickness at month 6. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
afliberceptdexamethasone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2600123418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123418.